Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders

Trends in Pharmacological Sciences

Volumn 30, Issue 3, 2009, Pages 148-155

  Conn, P Jeffrey ^a   Jones, Carrie K ^a   Lindsley, Craig W ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

77 LH 28 1; AC 42; AF 267; BENZYL QUINOLONE CARBOXYLIC ACID; BRUCINE; CHOLINESTERASE INHIBITOR; LY 2033298; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M4 RECEPTOR AGONIST; MUSCARINIC RECEPTOR; N (2,3 DIPHENYL 1,2,4 THIADIAZOL 5(2H) YLIDENE)METHANAMINE; NORCLOZAPINE; OXOTREMORINE; TACRINE; TBPB; THIOCHROME; UNCLASSIFIED DRUG; VU 0010010; VU 0029767; VU 0090157; VU 0152009; VU 0152100; XANOMELINE;

ALLOSTERISM; ALZHEIMER DISEASE; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRADYCARDIA; CENTRAL NERVOUS SYSTEM DISEASE; CHO CELL; COGNITIVE DEFECT; CONCENTRATION RESPONSE; DIFFUSE LEWY BODY DISEASE; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSALIVATION; MULTIINFARCT DEMENTIA; NEGATIVE SYNDROME; NONHUMAN; PARKINSON DISEASE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; SWEATING; TREATMENT RESPONSE;

ALLOSTERIC REGULATION; ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; HUMANS; MENTAL DISORDERS; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M4; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA;

EID: 61349093537     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.12.002     Document Type: Review

References (54)

1. Brown T.A., and Zador A.M. Hippocampus. In: Shepherd G.M. (Ed). The Synaptic Organization of the Brain (1990), Oxford University Press 346-388
2. Cooper J., et al. The Biochemical Basis of Neuropharmacology (1996), Oxford University Press
3. Hasselmo M.E. The role of acetylcholine in learning and memory. Curr. Opin. Neurobiol. 16 (2006) 710-715
4. Pisani A., et al. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 30 (2007) 545-553
5. 1 receptors. Neurodegener. Dis. 5 (2008) 237-240
6. Langmead C.J., et al. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 117 (2008) 232-243
7. Bymaster F.P., et al. Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur. J. Neurosci. 17 (2003) 1403-1410
8. Katzenschlager, R. et al. (2003) Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst. Rev., CD003735
9. Wess J., et al. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug Discov. 6 (2007) 721-733
10. Barten D.M., and Albright C.F. Therapeutic strategies for Alzheimer's disease. Mol. Neurobiol. 37 (2008) 171-186
11. Felder C.C., et al. Therapeutic opportunities for muscarinic receptors in the central nervous system. J. Med. Chem. 43 (2000) 4333-4353
12. 1 muscarinic acetylcholine receptor reduces amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 28 (2008) 10422-10433
13. Conn P.J., et al. Allosteric modulators of GPCRs as a novel approach for treatment of CNS disorders. Nat. Rev. Drug Discov. 8 (2009) 41-54
14. May L.T., et al. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 1-51
15. Jakubik J., et al. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 52 (1997) 172-179
16. 1 muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 308 (2004) 830-837
17. 4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 65 (2004) 257-266
18. Lazareno S., et al. Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol. Pharmacol. 53 (1998) 573-589
19. Fawzi A.B., et al. SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol. Pharmacol. 59 (2001) 30-37
20. 1 muscarinic receptor. Mol. Pharmacol. 61 (2002) 1297-1302
21. Sur C., et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13674-13679
22. 1 allosteric muscarinic receptor agonist in vitro and produces robust antypsychotic-like effects in vivo. Neuropsychopharmacology 31 (2006) S117
23. Kinney G.G. Muscarinic receptor activiation for the treatment of schizophrenia. Neuropsychopharmacology 31 (2006) S26
24. 1 muscarinic receptor agonist, 77-LH-28-1. Br. J. Pharmacol. 154 (2008) 1104-1115
25. 1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. J. Pharmacol. Exp. Ther. 327 (2008) 365-374
26. Caccamo A., et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49 (2006) 671-682
27. 1 muscarinic acetylcholine receptors. Mol. Pharmacol. http://molpharm.aspetjournals.org 10.1124/mol.108.050963
28. Chen Y., et al. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol. Pharmacol. 73 (2008) 909-918
29. 1 allosteric agonist TBPB. Part I. Exploration of alternative benzyl and privileged structure moieties. Bioorg. Med. Chem. Lett. 18 (2008) 5439-5443
30. 1 allosteric agonist TBPB. Part II. Amides, sulfonamides and ureas: the effect of capping the distal basic piperidine nitrogen. Bioorg. Med. Chem. Lett. 18 (2008) 5444-5449
31. 1 muscarinic receptors reveals multiple modes of activity. Mol. Pharmacol. http://molpharm.aspetjournals.org 10.1124/mol.108.052886
32. 1 muscarinic receptor provides unprecedented selectivity and a novel therapeutic strategy for the treamtent of alzheimer's disease. Alzheimers Dement. 4 Suppl. 1 (2008) T761
33. 1 receptor modulator. Alzheimers Dement. 4 Suppl. 1 (2008) T770
34. Bodick N.C., et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 54 (1997) 465-473
35. Bodick N.C., et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 11 Suppl. 4 (1997) S16-S22
36. Assal F., and Cummings J.L. Neuropsychiatric symptoms in the dementias. Curr. Opin. Neurol. 15 (2002) 445-450
37. Bullock R., and Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr. Med. Res. Opin. 18 (2002) 258-264
38. Feldman H. Treating Alzheimer's disease with cholinesterase inhibitors: what have we learned so far?. Int. Psychogeriatr. 14 Suppl. 1 (2002) 3-5
39. Grossberg G.T. The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Int. Psychogeriatr. 14 Suppl. 1 (2002) 27-49
40. Kaufer D. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9 Suppl. 2 (1998) 8-14
41. Mirza N.R., et al. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 9 (2003) 159-186
42. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int. J. Clin. Pract. Suppl. (2002) 20-36
43. Shekhar A., et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 165 (2008) 1033-1039
44. 1 muscarinic receptor mutant mice. Nat. Neurosci. 6 (2003) 51-58
45. Felder C.C., et al. Elucidating the role of muscarinic receptors in psychosis. Life Sci. 68 (2001) 2605-2613
46. 1 muscarinic acetylcholine receptor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 15312-15317
47. Marino M.J., and Conn P.J. Direct and indirect modulation of the N-methyl d-aspartate receptor. Curr. Drug Target. CNS Neurol. Disord. 1 (2002) 1-16
48. Messer Jr. W.S. Cholinergic agonists and the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 2 (2002) 353-358
49. 1 muscarinic acetylcholine receptor. J. Neurosci. 21 (2001) 5239-5250
50. 4 mAChR modulates hippocampal synaptic transmission. Nat. Chem. Biol. 4 (2008) 42-50
51. 4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotion behavior in rats. J. Pharmacol. Exp. Ther. 327 (2008) 941-953
52. 4 receptor as an approach to treating schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10978-10983
53. O'Brien J.A., et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). Mol. Pharmacol. 64 (2003) 731-741
54. Sharma S., et al. Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorg. Med. Chem. Lett. 18 (2008) 4098-4101